Key Points
- On Dec. 9, Moderna director Abbas Hussain sold 504 shares at an average price of $27.60 for $13,910.40, cutting his ownership by 24.96% to 1,515 shares (valued at about $41,814).
- Moderna shares traded around $30.05 as the company beat EPS estimates (‑$0.51 vs. ‑$2.15) with $1.02B in revenue, but revenue fell 45.4% year‑over‑year, margins remain deeply negative, and analysts' consensus rating is "Reduce" with an average price target of $29.50.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Abbas Hussain sold 504 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.60, for a total value of $13,910.40. Following the sale, the director directly owned 1,515 shares in the company, valued at $41,814. This trade represents a 24.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Moderna Trading Up 1.4%
NASDAQ:MRNA traded up $0.42 during mid-day trading on Friday, reaching $30.05. The company's stock had a trading volume of 1,512,345 shares, compared to its average volume of 10,825,545. The stock has a market cap of $11.74 billion, a P/E ratio of -3.72 and a beta of 1.11. The firm's fifty day moving average price is $26.02 and its two-hundred day moving average price is $27.03. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $48.92.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. During the same quarter last year, the firm posted $0.03 EPS. The business's quarterly revenue was down 45.4% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.
Analysts Set New Price Targets
MRNA has been the subject of a number of research reports. Bank of America lowered their price target on Moderna from $24.00 to $21.00 and set an "underperform" rating on the stock in a report on Monday, November 10th. Citigroup reduced their price objective on Moderna from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Thursday, October 23rd. UBS Group reissued a "buy" rating on shares of Moderna in a research report on Friday, November 21st. Jefferies Financial Group began coverage on Moderna in a research note on Friday. They set a "hold" rating and a $30.00 price target for the company. Finally, Piper Sandler reiterated an "overweight" rating on shares of Moderna in a research note on Monday, December 1st. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $29.50.
Read Our Latest Research Report on Moderna
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in MRNA. S Bank Fund Management Ltd bought a new position in shares of Moderna during the 1st quarter valued at approximately $25,000. Rothschild Investment LLC lifted its holdings in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company's stock valued at $25,000 after purchasing an additional 446 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock valued at $26,000 after purchasing an additional 743 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Moderna in the second quarter worth approximately $26,000. Finally, SVB Wealth LLC purchased a new stake in shares of Moderna in the first quarter worth $28,000. Institutional investors own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
